A significant trend was demonstrated in that patients with SKCM exhibiting higher ELP6 levels displayed greater sensitivity to AZ628 and sorafenib inhibitors compared with those with lower ELP6 levels ( Fig. 5A and B ).
← all excerpts
Role of ELP6 in tumour progression and impact on ERK1/2 signalling pathway inhibitors in skin cutaneous melanoma.
1
—
—